Silence Therapeutics is a company that makes medicine to help people with bad cholesterol levels in their blood. They were working on a new drug called SLN501, but another company named Mallinckrodt decided not to work on it anymore. This made Silence Therapeutics' stock price go down because investors are worried about how much money the company will make from selling their other medicine called zerlasiran. The company also told people that they lost some money in 2023, but less than before. They still have some money left to keep working on their medicines and hope to do better in the future. Read from source...

1. The title is misleading and sensationalized. It implies that there is something dramatic or negative happening with Silence Therapeutics stock today, but the article does not provide any concrete evidence of that. Instead, it mentions past events and ongoing developments that are unrelated to the current trading session.
2. The author uses vague and ambiguous terms like "not pursue further development" and "topline 36-week data". These phrases do not convey any clear information or insight into the company's performance, strategy, or outlook. They also create confusion and uncertainty among readers who may not be familiar with the industry jargon or the specific details of the phase 1 study or the phase 2 study.
3. The author fails to provide any context or background for the reader to understand why Mallinckrodt's decision is relevant or impactful for Silence Therapeutics and its shareholders. What was the nature of the collaboration between the two companies? How did it benefit or harm either party? Why did Mallinckrodt change their mind? What are the implications for the future development of SLN501 or zerlasiran? These questions remain unanswered and leave a gap in the analysis.
4. The author jumps from one topic to another without any logical connection or transition. The article starts with Mallinckrodt's announcement, then moves on to Silence Therapeutics' financial results for 2023, then mentions some collaboration revenues and net loss figures, but does not explain how they relate to the main theme of the article or the performance of the stock. The reader is left wondering why these details are included and what they mean for the company's prospects.
5. The author uses outdated information and irrelevant data in some places. For example, the financial results for 2023 are reported as if they were just released, but the article is dated March 13, 2024. This creates a discrepancy and undermines the credibility of the source. Also, the mention of "free newsletter" at the end of the article seems to be an advertisement or a promotional tactic that has nothing to do with the content or quality of the journalism.
6. The author does not provide any sources or citations for the information presented in the article. This makes it difficult to verify or corroborate the accuracy or reliability of the data, claims, or opinions expressed in the article. It also raises ethical concerns about plagiarism or copyright infringement if the author has used someone else's work without proper attribution.
7. The author does not offer any analysis, interpretation, or evaluation of the information presented

Negative
Reasoning: The article discusses the stock price decline of Silence Therapeutics due to Mallinckrodt's decision not to pursue further development of SLN501 and reports the company's financial results for 2023. Both factors contribute to a negative sentiment around the company and its prospects.